EZH2 and hepatocellular carcinoma: AGO promotes cell proliferation and angiogenesis in HCC (27, 28); silencing HNRNPC inhibits proliferation, migration, and invasion of HCC cells (29); EZH2 enhances protein kinase B activation to promote HCC progression (30); SFPQ plays an important role in the enhancement of fatty acid biosynthesis by NONO to promote HCC progression (31); and SRSF1 promotes HCC development, which can be regulated by MALAT1 (32, 33).